Cue Biopharma Reports Third Quarter 2026 Financial Results and Recent

Cue Biopharma, Inc. (CUE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cue Biopharma Reports Third Quarter 2026 Financial Results and Recent Business Highlights • CUE-221 Phase 2 chronic spontaneous urticaria (CSU) findings highlight differentiated clinical benefit and potential to expand the addressable patient population in CSU and fo

Event · Earnings
Original reporting
Published Nov 16, 2026, 9:52 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 11:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$CUE
Bullish
medium confidence
Mentioned
$CUE
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$CUEBullishMed
01

Why it matters

For traders, the key decision inputs are the newly disclosed Phase 2 CSU endpoint results for CUE-221, the FDA-cleared IND for food allergy, and the start of first-in-human dosing for CUE-401, alongside a clear picture of accelerating operating expenses and net loss.

02

Market read

This is a company-specific biotech catalyst filing combining clinical topline data, IND clearance, first dosing, and a financial burn update, which can drive near-term repricing of pipeline value and financing expectations.

03

What to watch

Cash and cash equivalents are only $57.9M as of Sept 30, 2026, while R&D and G&A expenses surge, increasing dilution or financing risk before later-stage milestones.

Relevance 7/10Novelty 8/10Timing: after-hours filing on Nov 16, 2026, with clinical and financial disclosures

Background

The 8-K (Item 2.02 with Exhibit 99.1) furnishes Cue Biopharma’s Q3 2026 financial results and portfolio updates for its lead programs CUE-221 (CSU and food allergy) and CUE-401 (autoimmune).

Company-level read

Ticker impact

$CUEBullishMedium confidence
Context

Cue Biopharma reports Q3 2026 results and discloses Phase 2 CSU topline endpoints for CUE-221 plus first-in-human dosing initiation for CUE-401.

Expected impact

Shares may face upward pressure as investors price in differentiated CUE-221 efficacy and de-risking of CUE-401 entry into the clinic, tempered by widening losses and declining revenue.

Evidence & confidence

The filing includes statistically significant CSU endpoints (HSS7=0, UAS7=0), a defined 4 mg/kg differentiated dose vs placebo and post-hoc comparison to Xolair, plus an FDA-cleared IND for food allergy and first-in-human dosing for CUE-401. Financials show sharply higher R&D and G&A and a larger net loss, which can cap upside.

Market effects

Adds incremental competitive and mechanistic validation for anti-IgE and dual-mechanism approaches in CSU, potentially influencing sentiment toward early-stage immune-mediated disease developers.

Primarily impacts US small-cap biotech sentiment and Nasdaq biotech flow rather than broad regional indices.

Limited direct global macro linkage; relevance is mainly for global investors tracking immune-mediated allergy and autoimmune pipeline progress.

Counterpoint

The Phase 2 CSU claims are topline and include post-hoc comparisons; investors may discount durability and generalizability until full datasets and confirmatory trials.

Key entities

  • Cue Biopharma, Inc.

    Nasdaq-listed clinical-stage biopharmaceutical company reporting Q3 2026 results and pipeline milestones.

  • CUE-221

    Phase 2 CSU candidate with topline endpoints reported, plus FDA-cleared IND for food allergy advancement.

  • CUE-401

    Lead autoimmune candidate that has initiated first-in-human Phase 1 dosing.

  • FDA

    Cleared the IND application for Cue’s food allergy program.

Related articles

$CUEMedAI 8/10

Cue Biopharma (CUE) Reports Hives Drug Results. Can Longer Relief Set it Apart?

Cue Biopharma (CUE) reported positive Phase 2 results for CUE-221 in treating chronic hives, with 54% of patients achieving complete hive resolution vs. 11% on placebo. The drug showed sustained relief 12 weeks post-treatment, with 60% of patients in the highest-dose group remaining hive-free. No serious adverse events were reported. The company plans a Phase 2b/3 study and has $67.4M in cash after recent financing.

$CUEMedAI 9/10

Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria

Cue Biopharma, Inc. (CUE) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria Results support potential for differentiated clinical impact for patients suffering from chronic hives and advancement to Phase 2b/3 registration enabling stu